Lan-Yun Yan1, Qing-Fang He2, Min-Yan Lu2, Sheng-Long Wang2, Zhi-Qiang Qi2, Hai-Rong Dong1,2. 1. Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. 2. Department of Neurology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou 215228, China.
Abstract
BACKGROUND: Epidemiological studies show that patients with Parkinson's disease (PD) are prone to have a reduced incidence of ischemic cerebrovascular disease. Previous studies show the correlation between PD and the lipids serum levels. The PD,s patients are found with a reduced serum level of triglyceride and low-density lipoprotein cholesterol (LDL-C); thus, the level of serum uric acid (UA) is closely related to the occurrence and development of PD. Patients with low serum UA levels have a higher chance of developing PD than the ones who do not. However, the relationship between carotid plaques and PD is still unknown. METHODS: Our study was based on 68 patients with PD (known as the PD group) and 81 people without PD (known as the control group). Patients in the PD group were of the same age and gender. Both groups were recorded and analyzed for UA, LDL-C, and carotid plaques or intima-media thickness (IMT). The PD group was then divided into three subgroups: the stable plaque group, the unstable plaque group, and the non-plaque group. RESULTS: In the present study, the PD group showed a significantly lower level of UA and LDL-C than the control group (P<0.01); somehow there were no statistically significant differences in the IMT and plaque incidence between the two groups (P>0.05). There were also no significant differences (P>0.05) in both the LDL-C and UA levels in all subgroups, but there was a close relation in both age and duration of disease to IMT. According to the Hoehn and Yahr staging scale, serum levels of LDL-C were inversely correlated in PD patients, while UA was related to the duration of the disease. CONCLUSIONS: Our study suggested that there were no differences in carotid artery arteriosclerosis plaque and IMT, but the PD progress was indeed correlated with IMT. Meanwhile, LDL-C and UA had different priorities in H&Y and disease progression.
BACKGROUND: Epidemiological studies show that patients with Parkinson's disease (PD) are prone to have a reduced incidence of ischemic cerebrovascular disease. Previous studies show the correlation between PD and the lipids serum levels. The PD,s patients are found with a reduced serum level of triglyceride and low-density lipoprotein cholesterol (LDL-C); thus, the level of serum uric acid (UA) is closely related to the occurrence and development of PD. Patients with low serum UA levels have a higher chance of developing PD than the ones who do not. However, the relationship between carotid plaques and PD is still unknown. METHODS: Our study was based on 68 patients with PD (known as the PD group) and 81 people without PD (known as the control group). Patients in the PD group were of the same age and gender. Both groups were recorded and analyzed for UA, LDL-C, and carotid plaques or intima-media thickness (IMT). The PD group was then divided into three subgroups: the stable plaque group, the unstable plaque group, and the non-plaque group. RESULTS: In the present study, the PD group showed a significantly lower level of UA and LDL-C than the control group (P<0.01); somehow there were no statistically significant differences in the IMT and plaque incidence between the two groups (P>0.05). There were also no significant differences (P>0.05) in both the LDL-C and UA levels in all subgroups, but there was a close relation in both age and duration of disease to IMT. According to the Hoehn and Yahr staging scale, serum levels of LDL-C were inversely correlated in PD patients, while UA was related to the duration of the disease. CONCLUSIONS: Our study suggested that there were no differences in carotid artery arteriosclerosis plaque and IMT, but the PD progress was indeed correlated with IMT. Meanwhile, LDL-C and UA had different priorities in H&Y and disease progression.
Authors: Wenzhen Duan; Bruce Ladenheim; Roy G Cutler; Inna I Kruman; Jean Lud Cadet; Mark P Mattson Journal: J Neurochem Date: 2002-01 Impact factor: 5.372
Authors: Clifford W Shults; David Oakes; Karl Kieburtz; M Flint Beal; Richard Haas; Sandy Plumb; Jorge L Juncos; John Nutt; Ira Shoulson; Julie Carter; Katie Kompoliti; Joel S Perlmutter; Stephen Reich; Matthew Stern; Ray L Watts; Roger Kurlan; Eric Molho; Madaline Harrison; Mark Lew Journal: Arch Neurol Date: 2002-10
Authors: Paul S Fitzmaurice; Lee Ang; Mark Guttman; Ali H Rajput; Yoshiaki Furukawa; Stephen J Kish Journal: Mov Disord Date: 2003-09 Impact factor: 10.338
Authors: Michael V Miles; Paul S Horn; John A Morrison; Peter H Tang; Ton DeGrauw; Amadeo J Pesce Journal: Clin Chim Acta Date: 2003-06 Impact factor: 3.786
Authors: Jasjit S Suri; Mahesh A Maindarkar; Sudip Paul; Puneet Ahluwalia; Mrinalini Bhagawati; Luca Saba; Gavino Faa; Sanjay Saxena; Inder M Singh; Paramjit S Chadha; Monika Turk; Amer Johri; Narendra N Khanna; Klaudija Viskovic; Sofia Mavrogeni; John R Laird; Martin Miner; David W Sobel; Antonella Balestrieri; Petros P Sfikakis; George Tsoulfas; Athanase D Protogerou; Durga Prasanna Misra; Vikas Agarwal; George D Kitas; Raghu Kolluri; Jagjit S Teji; Mustafa Al-Maini; Surinder K Dhanjil; Meyypan Sockalingam; Ajit Saxena; Aditya Sharma; Vijay Rathore; Mostafa Fatemi; Azra Alizad; Padukode R Krishnan; Tomaz Omerzu; Subbaram Naidu; Andrew Nicolaides; Kosmas I Paraskevas; Mannudeep Kalra; Zoltán Ruzsa; Mostafa M Fouda Journal: Diagnostics (Basel) Date: 2022-06-24